Shares of Galapagos NV (NASDAQ:GLPG - Get Free Report) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $27.36 and traded as low as $27.12. Galapagos shares last traded at $27.38, with a volume of 66,817 shares trading hands.
Wall Street Analyst Weigh In
A number of equities analysts have commented on GLPG shares. Leerink Partners assumed coverage on shares of Galapagos in a report on Monday, September 9th. They issued a "market perform" rating and a $24.00 target price for the company. Kepler Capital Markets lowered shares of Galapagos from a "hold" rating to a "reduce" rating in a research note on Wednesday, November 20th. Royal Bank of Canada lowered their target price on shares of Galapagos from $32.00 to $30.00 and set a "sector perform" rating for the company in a research note on Friday, November 1st. Finally, Leerink Partnrs raised Galapagos to a "hold" rating in a research report on Monday, September 9th. Two analysts have rated the stock with a sell rating and six have given a hold rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $30.75.
View Our Latest Analysis on Galapagos
Galapagos Price Performance
The stock has a 50-day moving average of $27.52 and a 200 day moving average of $27.36.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the business. Erste Asset Management GmbH acquired a new stake in Galapagos during the 3rd quarter worth about $410,000. Finepoint Capital LP grew its holdings in Galapagos by 2.8% during the third quarter. Finepoint Capital LP now owns 557,762 shares of the biotechnology company's stock worth $16,058,000 after acquiring an additional 15,000 shares during the period. Crossmark Global Holdings Inc. purchased a new position in Galapagos during the third quarter valued at approximately $1,077,000. QRG Capital Management Inc. acquired a new position in Galapagos in the third quarter valued at approximately $247,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in Galapagos by 63.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,899 shares of the biotechnology company's stock worth $112,000 after purchasing an additional 1,510 shares in the last quarter. Hedge funds and other institutional investors own 32.46% of the company's stock.
Galapagos Company Profile
(
Get Free Report)
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
Read More
Before you consider Galapagos, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galapagos wasn't on the list.
While Galapagos currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
